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In a linked article, Møller and colleagues1 present a neat analysis
of the use of the fast track referral pathway for patients with
suspected cancer in 2009 (two week wait system) by English
general practices and subsequent cancer mortality in patients
from these practices. In 2009, this fast track pathway enabled
access to a specialist opinion or diagnostic test within two weeks
for eligible patients. Møller and colleagues studied three
measures: the referral ratio (each practice’s use of the two week
wait system compared with other practices), detection rate
(percentage of cancers in a practice that were detected via the
two week clinics), and conversion rate (proportion of patients
whowent through the twoweekwait system andwhowere then
shown to have cancer). Practices with a high referral ratio and
those with a high detection rate had reduced cancer mortality,
although the conversion rate showed no association.
Cancer survival in England has steadily improved since 1995,
and this improvement is accelerating.2 Even so, we remain
stubbornly behind other European countries, although the gap
is narrowing for some cancers.2 This improvement is
accompanied by a reduction in emergency presentations for
cancer, from 25% overall in 2006, to 20% by 2013.3 Times to
diagnosis of cancer have also fallen, although largely for patients
whose symptoms made them eligible for a two week wait
appointment under the old guidelines from the National Institute
for Health and Care Excellence (NICE).3-5
Furthermore, diagnostic activity for cancer has risen relentlessly
in primary care, with a 29% increase between 2010 and 20136
and now over a million two week wait appointments occurring
annually. The conversion rate in these clinics is falling steadily,
but is matched by an increased detection rate. This is
accompanied by rapid increases in imaging and endoscopy, to
the extent that these services are struggling to meet demand.7 8
It is tempting to conclude from the new study that increased use
of the urgent referral pathway leads to lower cancer mortality.
However, some of the reported association will be due to case
mix; given the relatively small numbers of new cancers annually
in any practice, random variation will mean that in some years,
a practice could have disproportionate numbers of so called
“easy” patients to diagnose.9 These patients will take the two
week referral route, obtain early diagnosis and treatment, avoid
emergency presentation with its extra mortality, and do well.10
For colorectal cancer, the optimum time between first reporting
of a symptom to primary care and eventual diagnosis is a
month,11 which equates to referral within two weeks, followed
by timely investigation. Only by repeating the study over
multiple years can we identify the precise contribution of case
mix to Møller and colleagues’ results.
The alternative interpretation for the study’s findings—which
is favoured by the authors—is that some practices have a higher
propensity to refer. Practices will use the two week pathway for
some patients at low risk but not no risk, who other practices
will choose not to refer. For this behaviour to explain the
findings, sufficient numbers of these additional patients would
have to harbour cancer, and their expedited diagnosis would
have to be accompanied by improved mortality. The size of the
improved mortality in the higher referring group (4%, 95%
confidence interval 1% to 6%) is compatible with this.
However, the extra patients referred would be expected to lower
the conversion rate, yet this rate was not associated with a
difference in mortality. The explanation is more powerful for
the low referring group of practices, who had 7% (confidence
interval 5% to 8%) worse mortality. If patients meeting the
previous NICE guidance were not being referred by this group,
and suffering as a result, then low referral ratios could be
associated with an unchanged conversion rate. Practices now
receive reports on several cancer metrics each year. Practices
with a consistently low use of the two week system should
consider why that is so.
Oddly, the precise explanation may not matter much: both
interpretations suggest that early diagnosis of symptomatic
cancer is beneficial, and that doing so via the two week system
helps. This is fortunate, because the revised NICE guidance has
liberalised access to these clinics, as well as expanding in-house
primary care testing.12 The public supports this direction, opting
for testing even if the risk of cancer was as low as 1%.13 Most
primary care clinicians also support the liberalisation of
investigation enshrined in the new NICE guidance, which has
partly reduced the gap between public expectation and what
was on offer in the NHS.Much of this liberalisation has occurred
already, prompted by awareness campaigns and multiple
initiatives in primary care. Furthermore, the new
recommendations explicitly support general practitioners’ use
W.Hamilton@exeter.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;351:h5311 doi: 10.1136/bmj.h5311 (Published 13 October 2105) Page 1 of 2
Editorials
EDITORIALS
of their clinical judgment, saving them from having to make
the patient fit the guidelines.12
The recent improvements in cancer diagnosis are real, large,
and welcome. A 5% reduction in the proportion of emergency
presentations is over 16 000 fewer cancer emergencies annually,
and this is only one component of the improvement. One major
question remains, however—the cost. Cancer diagnostics are
expensive, with perhaps £1bn (€1.35bn; $1.52bn) spent annually.
It has been difficult to quantify the survival benefit from
expedited diagnosis of symptomatic cancer. In simple terms,
we know what we are paying, but don’t know what we are
getting. At least now we know we are getting something for the
investment:Møller and colleagues’ study adds further evidence
to the survival and emergency admission figures, and all point
in the same direction. It is better to develop cancer in the United
Kingdom now than it was 10 years ago—and improved
diagnostic facilities are a part of the reason why. It may be even
better in another 10 years.
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